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Abstract
There is currently limited information available on the molecular epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in
South Africa. A molecular characterization of 100 MRSA from five hospitals in Cape Town was carried out in this study. The strains
were separated into six clusters by pulsed-field gel electrophoresis, indicating transmission of MRSA between local hospitals. None of
the strains carried the Panton-Valentine Leukocidin gene. SCCmec typing, multilocus sequence typing and spa typing were used to fur-
ther characterize the MRSA. Three clones corresponded to frequently described pandemic clones: ST239-MRSA-III, ST36-MRSA-II and
ST5-MRSA-I. ST239-MRSA-III and ST36-MRSA-II were minor clones and collectively accounted for 16% of the isolates. ST5-MRSA-I was
the second-most prevalent clone and accounted for 37% of the isolates. The dominant local clone was the infrequently described
ST612-MRSA-IV (44% of isolates), which has only been described in South Africa and Australia.
Keywords: Methicillin-resistant Staphylococcus aureus, MLST, SCCmec, ST612
Original Submission: 16 April 2010; Revised Submission: 30 August 2010; Accepted: 30 August 2010
Editor: G. Lina
Article published online: 20 September 2010
Clin Microbiol Infect 2011; 17: 785–792
10.1111/j.1469-0691.2010.03373.x
Corresponding author: B. Gay Elisha, Division of Medical Microbi-
ology, Faculty of Health Sciences, University of Cape Town, Anzio
Road, Observatory 7925, South Africa
E-mail: Gay.Elisha@uct.ac.za
Introduction
Methicillin-resistant S. aureus (MRSA) has become a major
public health problem worldwide [1,2], and South Africa is
no exception. The proportion of clinical S. aureus isolates
that are methicillin-resistant in South Africa ranges from 29%
to 46% [3,4]. Methicillin-resistance is conferred by mecA,
which is contained in a large mobile genetic element called
the staphylococcal cassette chromosome mec (SCCmec)
[2,5]. The SCCmec element has been acquired on numerous
occasions by a limited number of S. aureus lineages or clonal
complexes (CCs), including CC5, CC8, CC22, CC30 and
CC45 [6,7]. The global prevalence of MRSA is due to the
dissemination of pandemic clones, and SCCmec element cap-
ture by local methicillin-susceptible S. aureus (MSSA) [6–8].
Traditionally, MRSA is regarded as a nosocomial pathogen;
however, in recent decades, it has also emerged in the
community [1,2,5]. Although the differences between hospi-
tal-acquired MRSA (HA-MRSA) and community-acquired
MRSA (CA-MRSA) have become less distinct, the former
commonly contain SCCmec types I–III, and are often resis-
tant to non-b-lactam antibiotics. On the other hand, CA-
MRSA isolates typically contain SCCmec types IV, VI and VII,
often carry the Panton-Valentine Leukocidin (pvl) gene, and
are typically susceptible to non-b-lactam antibiotics [2,5].
Notwithstanding the characterization of MRSA from the
KwaZulu-Natal province [9,10], there is a paucity of compre-
hensive data on the molecular epidemiology of MRSA in
South Africa. This report describes the molecular epidemiol-
ogy of MRSA circulating in hospitals in Cape Town, in the
Western Cape province of South Africa.
Materials and Methods
Bacterial isolates
One hundred MRSA isolates, without duplication, obtained
between January 2007 and December 2008, were included in
the study. This represented 13.6% of MRSA isolates identi-
fied in the laboratory over the study period. The isolates
were cultured from pus and pus swabs (n = 64), urine
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(n = 9), respiratory tract specimens (n = 13), blood (n = 7)
and central venous catheter tips (n = 7). The specimen types
were broadly representative of those from which MRSA
were isolated during the study period and were obtained
from patients in any one of five hospitals in metropolitan
Cape Town: Groote Schuur Hospital (GSH, n = 51), Mow-
bray Maternity Hospital (MMH, n = 19), Red Cross War
Memorial Children’s Hospital (RCCH, n = 21), Victoria Hos-
pital (VH, n = 4) and University of Cape Town Private Hos-
pital (UCTPH, n = 5). The number of isolates from each
hospital was representative of the proportions isolated from
patients at each hospital.
GSH, RCCH and UCTPH are tertiary level hospitals with
bed capacities of 893, 240 and 112, respectively. These hos-
pitals offer a range of clinical services, including general medi-
cal and surgical, trauma and emergency, as well as
subspecialist medical and surgical services. VH (158 beds) is
a secondary level hospital offering emergency, trauma and
general medical and surgical services. Although MMH (179
beds) is a secondary level maternity hospital, tertiary neona-
tal care is offered. The study isolates were obtained from
patients in a range of wards, including outpatient clinics
(n = 15), emergency services (n = 4), medical (n = 16), surgi-
cal (n = 23), intensive care units (n = 20), and obstetrics and
gynaecology (n = 15). No ward was specified for seven of
the samples. The National Health Laboratory Service micro-
biology laboratory at GSH serves all five hospitals.
Definition of community-acquired MRSA
Although the purpose of the study was not to compare the
epidemiology of CA-MRSA with that of HA-MRSA, a rudi-
mentary approach was used to classify the isolates. Admis-
sion histories of all patients were reviewed using electronic
admission records. These records did not include a history
of prior admission to private health care facilities, nursing
facilities, or health care facilities outside the city of Cape
Town. MRSA isolated within 48 h of admission to a hospital,
from patients with no record of prior admission to a health
care facility, or contact with an outpatient clinic within the
previous 12 months, was classified as CA-MRSA. All others
were classified as HA-MRSA.
Isolate identification and antibiotic susceptibility testing
Isolates were identified either by the production of DNAse, or
on the VITEK 2 (bioMe´rieux, La Balme-les-Grottes, France).
Antimicrobial susceptibility testing was performed using disc
diffusion or the VITEK 2 system. Zone sizes or VITEK 2 MIC
results were interpreted using Clinical and Laboratory Stan-
dards Institute breakpoints [11,12], as well as the Advanced
Expert System of the VITEK 2.
Pulsed-field gel electrophoresis
Pulsed-field gel electrophoresis (PFGE) profiles were obtained
using the method described by Reed et al. [13] with the fol-
lowing modifications. Bacterial cell suspensions were stan-
dardized to an OD600 reading between 0.825 and 0.875.
Agarose plugs (width, 5mm; height, 2mm; and thickness,
1mm) were prepared with 2% SeaKem Gold Plug Agarose
(Cambrex Bio Science Rockland, Inc., Rockland, ME, USA).
Electrophoresis was carried out using a CHEF-DRII GeneNav-
igator (Amersham Biosciences, Fairfield, CT, USA) at a pulse
time of 5–60 s for 22 h at 200 V with 0.5· TBE maintained at
14C. Digital images were analysed using GelCompar II (ver-
sion 4.6) (Applied Maths BVBA, Sint-Martens-Latem, Belgium).
The images were normalized in comparison to the profile of
S. aureus NCTC8325. Only fragments within the normalized
region of each gel were included in the analysis [14]. A den-
drogram was created with the cluster analysis function using
the Dice similarity coefficient and unweighted pair-group
method, using averages (UPGMA) with a position tolerance
setting of 1% and an optimization value of 0.5%. PFGE clusters
were defined by a similarity level of at least 80% [13,14].
Detection of SCCmec types
Genomic DNA was isolated using the QIAamp DNA Mini kit
(Qiagen, Valencia, CA, USA). SCCmec types were deter-
mined by multiplex PCR [15]. Where necessary, atypical
amplification patterns were resolved using primers described
by Kondo et al. [16] to determine the combination of mec
class and ccr allotype present.
Detection of pvl
The presence of pvl was determined by PCR using primers
luk-PV-1 and luk-PV-2 as described by Lina et al. [17].
Multi-locus sequence typing and spa typing
Multilocus sequence typing (MLST) and spa typing were car-
ried out as previously described [18,19]. PCR products were
purified using the MinElute Gel Extraction kit (Qiagen) and
sequenced at the Central Analytical Facility at the University
of Stellenbosch. MLST sequence types (STs) were deter-
mined using the online database (http://www.mlst.net) while
spa types were determined with Ridom StaphType (version
1.5.21) (Ridom GmbH, Wu¨rzburg, Germany).
Results
PFGE profiles
The MRSA segregated into six PFGE clusters (A–F) and eight
sporadic isolates (Fig. 1). Sixty-eight per cent of the strains
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was almost equally distributed between clusters C (n = 35)
and E (n = 33). The remaining MRSA were assigned to clus-
ters A (n = 4), B (n = 2), D (n = 7) and F (n = 11). When
clusters were stratified by hospital, strains from cluster E
were identified in all of the hospitals (Table 1). Clusters C
and D included strains from three hospitals.
FIG. 1. Pulsed-field gel electrophoresis profiles and dendrogram showing the level of similarity between 100 methicillin-resistant Staphylococcus
aureus strains. Six clusters were identified and are indicated alongside each profile. Strain designations used in the text for isolates selected for
multilocus sequence typing and spa typing are indicated in brackets. Putative community-acquired isolates are indicated by *.
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SCCmec typing, MLST and spa typing
SCCmec types I and IV were identified in 37 strains (clusters
B and C) and 46 strains (clusters D and E). SCCmec types II
(cluster F) and III (cluster A) were observed in 11 and 4
strains, respectively (Table 1). SCCmec type IV was identified
in six sporadic isolates. SCCmec type II was identified in one
FIG. 1. (Continued)
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of the remaining sporadic isolates, whereas the other was
non-typable (NT).
MLST and spa typing were used to further characterize
the isolates. For these studies, a strain representative of each
of the PFGE clusters A, B, C, D and F was chosen. As vary-
ing levels of genetic similarity were observed within cluster
E, three strains were selected from this cluster. All sporadic
isolates were included in these investigations. The STs and
other relevant properties of the MRSA are presented in
Table 2.
Representatives of clusters A, B, C and F corresponded
to frequently described pandemic clones. MRSA from cluster
A corresponded to ST239-MRSA-III, spa type t037; B and C
corresponded to ST5-MRSA-I, t045, whereas ST36-MRSA-II
was identified for F (t012) and one sporadic isolate (t021).
Representative strains from clusters D and E, and four spo-
radic isolates, were consistent with the infrequently
described ST612-MRSA-IV clone. A number of spa types
were detected in the ST612-MRSA-IV strains (Table 2). Two
of the remaining sporadic isolates equated with ST72-MRSA-
NT, t3092, and ST22-MRSA-IV, t032, while the PFGE outlier,
designated strain S8, corresponded to ST650 and was a sin-
gle locus variant (SLV) of ST5 (varying at the arcC locus),
t002, with SCCmec type IV.
Antimicrobial susceptibility profiles
There were striking differences between the antimicrobial
susceptibility profiles of the clones (Table 3). Resistance to
gentamicin, co-trimoxazole, ciprofloxacin and rifampicin was
widespread in ST612-MRSA-IV strains, with 43 strains
(97.73%) resistant to three or more classes of antibiotics in
addition to the b-lactams (Table 3). In contrast, the ST5-
MRSA-I strains were generally susceptible to non-b-lactam
antibiotics, with the exception of erythromycin and clindamy-
cin (Table 3).
The detection of pvl
Ten isolates were classified as CA-MRSA: one from MMH,
six from RCCH and three from GSH. These isolates were
cultured from pus swabs (n = 6), urine (n = 3) and sputum
TABLE 1. Stratification of pulsed-
field gel electrophoresis (PFGE)
clusters by hospital PFGE cluster (no.) SCCmec
a type
Distribution of strains across hospitals [no. (%)]
GSHb RCCH MMH VH UCTPH
A (4) III 2 (50) 2 (50) – – –
B (2) I 1 (50) – – – 1 (50)
C (35) I 13 (37.1) 4 (11.4) 18 (51.4) – –
D (7) IV 4 (57.1) 2 (28.6) – 1 (14.3) –
E (33) IV 19 (57.6) 9 (27.3) 1 (3.0) 3 (9.1) 1 (3.0)
F (11) II 8 (72.7) – – – 3 (27.3)
aSCCmec, staphylococcal cassette chromosome mec.
bGSH, Groote Schuur Hospital; RCCH, Red Cross War Memorial Children’s Hospital; MMH, Mowbray Maternity
Hospital; VH, Victoria Hospital; UCTPH, University of Cape Town Private Hospital.
TABLE 2. Characteristics of MRSA strains selected for multilocus sequence typing and spa typing
MRSA
designationa
PFGEb cluster
(no. isolates)
SCCmecc
type
Antimicrobial
resistance profiled MLST (ST; CC)e spa type
A1 A (4) III PEN, OXA, ERY, CLI, SXT, CIP, GEN 239; 8 t037
B1 B (2) I PEN, OXA, ERY, CLI, GEN 5; 5 t045
C1 C (35) I PEN, OXA 5; 5 t045
D1 D (7) IV PEN, OXA, ERY, CLI, RIF, SXT, GEN 612; 8 t064
E1 E (33) IV PEN, OXA, RIF, SXT, CIP, GEN 612; 8 t1443
E2 E (33) IV PEN, OXA, ERY, CLI, RIF, SXT, CIP, GEN 612; 8 t2196
E3 E (33) IV PEN, OXA, RIF, SXT, CIP, GEN 612; 8 t1443
F1 F (11) II PEN, OXA, ERY, CLI, CIP 36; 30 t012
S1 Sporadic isolate IV PEN, OXA, RIF, SXT, CIP, GEN 612; 8 t1443
S2 Sporadic isolate Non-typable PEN, OXA, ERY, CLI 72; 8 t3092
S3 Sporadic isolate II PEN, OXA, ERY, CLI, CIP, GEN 36; 30 t021
S4 Sporadic isolate IV PEN, OXA, ERY, CLI, RIF, SXT, CIP, GEN 612; 8 t1257
S5 Sporadic isolate IV PEN, OXA, RIF, SXT, GEN 612; 8 t064
S6 Sporadic isolate IV PEN, OXA, RIF, SXT, GEN 612; 8 t064
S7 Sporadic isolate IV PEN, OXA, ERY, CLI, CIP 22; 22 t032
S8 Sporadic isolate IV PEN, OXA ST650f; 5 t002
aStrain designations of representative isolates as indicated in figure and text.
bPFGE, pulsed-field gel electrophoresis.
cSCCmec, staphylococcal cassette chromosome mec.
dPEN, penicillin; OXA, oxacillin; ERY, erythromycin; CLI, clindamycin; RIF, rifampicin; SXT, co-trimoxazole; CIP, ciprofloxacin; GEN, gentamicin.
eMLST, multilocus sequence typing; ST, sequence type; CC, clonal complex.
f Single locus variant of ST5 (varying at the arcC locus).
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(n = 1). Three and seven of the putative CA-MRSAs corre-
sponded to ST5-MRSA-I and ST612-MRSA-IV, respectively.
The pvl gene was not detected in any of the 100 isolates.
Discussion
To the best of our knowledge, this is the first study describ-
ing the molecular characteristics of MRSA from hospitals in
Cape Town, South Africa. One hundred MRSA isolates from
patients in five hospitals, including ten possible CA-MRSA,
were characterized in this study. The distribution of PFGE
clusters, SCCmec types and STs did not differ between the
HA-MRSA and putative CA-MRSA, and the pvl gene was not
detected in any of the isolates. This was consistent with pre-
vious studies in which this gene was either infrequently or
not detected in South African MRSA strains [10,20,21].
The MRSA segregated into six PFGE clusters and eight
sporadic isolates (Table 1 and Fig. 1). Each of the clusters
comprised strains from two or more hospitals, demonstrat-
ing transmission of strains within and between hospitals. Cli-
nicians commonly render clinical services at more than one
hospital, and this may represent one route by which MRSA
strains have disseminated across hospitals. Additionally, the
transfer of patients between hospitals is common practice
and almost certainly serves as a second means of spread.
Representatives of the PFGE clusters, and the sporadic
isolates, were characterized further using MLST and spa typ-
ing. Four clonal types, ST239-MRSA-III, ST36-MRSA-II, ST5-
MRSA-I and ST612-MRSA-IV, accounted for the majority of
the strains. The remaining three sporadic isolates designated
S2, S7 and S8 corresponded to: ST72-MRSA-NT, t3092,
ST22-MRSA-IV, t032, and ST650-MRSA-IV, t002.
With respect to sporadic isolates S2 and S8: ST72-MRSA
isolates have been described in Europe, the United States of
America and Brazil; in these countries the lineage is typically
associated with SCCmec type IV [22,23]. ST72 has also
become prevalent in Korea, where isolates containing either
SCCmec type II or IV have been described [24]. S8, ST650-
MRSA, contained SCCmec type IV and was susceptible to all
non-b-lactam antibiotics, which are characteristics typical of
CA-MRSA, suggesting that this strain could have originated
in the community. However, the available admissions data
suggested that infection was nosocomially acquired.
ST239-MRSA-III, which has been assigned numerous moni-
kers, including Brazilian/Hungarian, was a major pandemic
clone in Europe and South America during the 1990s [25]
and the second major clone recovered from health care facil-
ities in the KwaZulu-Natal province, South Africa, between
2001 and 2003 [10]. However, it was the smallest clonal type
identified in this study, including only four strains. Based on
recent studies on the population structure of ST239-MRSA-
III [25], this clone was probably imported into South Africa.
The representative of 11 MRSA isolates in cluster F (F1,
Fig. 1), and one sporadic isolate, S3, corresponded to ST36-
MRSA-II. This clone, also called EMRSA-16, has been reported
in South Africa [4,20] and was one of the predominant noso-
comial clones circulating in the United Kingdom (UK) [26]. It
has been proposed that the spread of EMRSA-16 to Spain and
Malta resulted from travel between the countries [27]. With a
history of emigration from the UK to South Africa, and tour-
ism between the two countries, it is likely that EMRSA-16 was
imported into South Africa from the UK. The sporadic isolate,
ST22-MRSA-IV, identified in one local hospital may have trav-
elled a similar route. This clone, also known as EMRSA-15, has
spread worldwide since it was first reported as epidemic in
hospitals in the UK [2,26].
ST5-MRSA-I (EMRSA-3), a pandemic clone described
worldwide [2], was the second-most prevalent clone in Cape
Town hospitals. Although ST5-MRSA strains have been iden-
tified previously in South Africa, they contained SCCmec
types III or IV [9,10]. To the best of our knowledge, this is
only the second report of ST5-MRSA-I in South Africa [8–
10]. It is interesting to consider the origin of local ST5-
MRSA-I strains in the light of the study reported by Nu¨bel
et al. [8]. Their study suggested that geographical dispersal of
ST5-MRSA has been limited, and this clone has emerged on
several occasions in geographically distinct regions. While it
is possible that local ST5-MRSA-I strains were imported from
another region, the possibility that the clone emerged fol-
lowing the acquisition of SCCmec type I by MSSA in hospitals
in Cape Town should also be considered.
TABLE 3. Antimicrobial susceptibility profiles of predominant clonal types
Clonal type PFGE cluster (no. isolates)
Antimicrobial agents (no. (%) resistant)
ERY CLI RIF SXT CIP GEN
ST239-MRSA-III A (4) 4 (100) 4 (100) 0 4 (100) 4 (100) 4 (100)
ST5-MRSA-I B, C (2, 35) 34 (91.9) 34 (91.9) 1 (2.7) 1 (2.7) 1 (2.7) 11 (29.7)
ST612-MRSA-IV D, E (7, 33) 18 (45) 16 (40) 40 (100) 38 (95) 29 (72.5) 36 (90)
ST36-MRSA-II F (11) 11 (100) 11 (100) 1 (9.1) 0 10 (90.9) 3 (27.3)
ERY, erythromycin; CLI, clindamycin; RIF, rifampicin; SXT, co-trimoxazole; CIP, ciprofloxacin; GEN, gentamicin.
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The infrequently described ST612-MRSA-IV was the domi-
nant clone circulating in hospitals in Cape Town. To the best
of our knowledge, this clone, a member of CC8, has been
described only in South Africa and Australia, and then only
twice in each country [20, http://www.mlst.net]. That the
geographical scatter of ST612 may be limited is supported by
recent studies [8,28,29], which showed that certain S. aureus
lineages are largely endemic to particular regions. Given the
degree of genetic variation revealed by PFGE, in addition to
the number of spa types detected for ST612-MRSA-IV
strains, it is possible to suggest that this is an old local clone
that has accumulated genetic variation over time and under-
gone clonal expansion.
All of the local ST612-MRSA-IV strains were resistant to a
number of antibiotics, including rifampicin and co-trimox-
azole. A similar level of resistance to these antibiotics was
observed in MRSA strains from hospitals in the KwaZulu-
Natal and Gauteng provinces [10,30]. Interestingly, the
majority of resistant isolates from the former study had STs
closely related to ST612 and also carried SCCmec type IV
[10]. It is tempting to suggest that these MRSAs are best fit-
ted to the current South African environment where rifampi-
cin is commonly prescribed for the treatment of
tuberculosis, and co-trimoxazole for the prophylaxis or
treatment of Pneumocystis infections in HIV-positive persons.
It is interesting to consider the relatedness of local
ST612-MRSA-IV to the previously described isolates from
South Africa and Australia. No clinical data were available
for the previously described ST612-MRSA-IV. Laboratory
information showed that they were resistant to rifampicin.
An investigation of the mechanism of resistance to rifampicin
in these strains, and nine ST612-MRSA-IV identified in this
study, revealed that all isolates had two amino acid substitu-
tions (H481N, I527M), which are associated with high level rif-
ampicin resistance (data not shown). Further, two
synonymous single nucleotide polymorphisms were identified
in the rifampicin-resistance determining region in all 13 iso-
lates. Additionally, the two ST612-MRSA-IV previously iso-
lated in South Africa, and one of the Australian strains, had
spa type t064, which was identified in three of the local iso-
lates. Taken together the data suggest that the isolates from
Cape Town may share a common ancestor with previously
described ST612-MRSA-IV isolates, but further studies are
necessary for confirmation.
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